Rare Respiratory Infections as Causes of Reactive Arthritis

Review article

Saša Janjić, Ana Đokić, Milena Đokić, Ana Marković, Anđela Peruničić, Tatjana Dimić, Mirjana Zlatković Švenda, Slavica Pavlov Dolijanović

35–42

https://doi.org/10.5937/medrec2601035J

ORCID iDs:             Saša Janjić                            N/A
Ana Đokić                           https://orcid.org/0009-0007-9937-0739
Milena Đokić                       https://orcid.org/0009-0009-2410-336­6
Ana Marković                      https://orcid.org/0009-0004-9828-1839
Anđela Peruničić                  https://orcid.org/0009-0009-4645-6074
Tatjana Dimić                      https://orcid.org/0009-0002-5969-3676
Mirjana Zlatković Švenda      https://orcid.org/0000-0002-7123-140X
Slavica Pavlov Dolijanović     https://orcid.org/0009-0005-5683-2193

Abstract

Reactive arthritis (ReA) is an immune-mediated, aseptic arthritis that may develop within a period ranging from 3 days to 6 weeks following any extra-articular infection. Although it is most commonly precipitated by gastrointestinal or genitourinary infections, in the aftermath of the SARS-CoV-2 pandemic, increasing attention has been directed toward the role of respiratory pathogens in the development of this condition. Accordingly, the aim of this review is to present current knowledge regarding rare respiratory pathogens associated with ReA, with particular emphasis on their clinical relevance and diagnostic and therapeutic implications. A systematic search of the relevant scientific literature was conducted using the Medline database, with a particular focus on the period from 2020 to 2025, in order to identify and analyze cases of ReA occurring in the context of respiratory infections, primarily those caused by rare respiratory pathogens. The analysis included individual case reports, original research articles, and review papers documenting the occurrence of ReA following respiratory infections. The most frequently identified respiratory pathogens were SARS-CoV-2, Chlamydophila pneumoniae, Streptococcus pyogenes, Parvovirus B19, and Mycoplasma pneumoniae, with a variable time interval between infection and the onset of arthritis (ranging from several days to several weeks). Less common respiratory pathogens included Streptococcus pneumoniae, Neisseria meningitidis, Rothia mucilaginosa, Haemophilus influenzae, and Mycobacterium tuberculosis. The clinical presentation of ReA associated with these pathogens did not differ substantially from that of typical etiologies; however, differences were observed in symptom duration and therapeutic response. In most cases, arthritis was oligoarticular, asymmetric, and accompanied by systemic signs of inflammation. Therapeutic approaches included nonsteroidal anti-inflammatory drugs, corticosteroids, and, in selected cases, antibiotics and immunosuppressive agents. ReA triggered by rare respiratory pathogens represents a diagnostic challenge. Although these pathogens are less frequently identified, their role in the etiopathogenesis of ReA warrants additional attention, given the potential for an atypical disease course and the need for individualized therapeutic strategies. The limited number of available case reports and other scientific publications highlights the need for further research and for the standardization of diagnostic criteria in this field.

Key words: reactive arthritis, rare respiratory pathogens
post-infectious arthritis

Full text 

Literatura

  1. Jubber A, Moorthy A. Reactive arthritis: a clinical review. J R Coll Physicians Edinb 2021;51(3):288–97.
  2. Bekaryssova D, Yessirkepov M, Zimba O, Gasparyan AY, Ahmed S. Reactive arthritis before and after the onset of the COVID-19 pandemic. Clin Rheumatol 2022;41(6):1641–52.
  3. Abraham P, Marin G, Filleron A, Michon AL, Marchandin H, Godreuil S, et al. Evaluation of post-infectious inflammatory reactions in a retrospective study of 3 common invasive bacterial infections in pediatrics. Medicine (Baltimore) 2022;101(38):e30506.
  4. Märker-Hermann E. Reaktive Arthritis – eine vergessene Erkrankung? [Reactive arthritis – a disease almost forgotten?]. Dtsch Med Wochenschr 2020;145(24):1786–90.
  5. Zeidler H, Hudson AP. Reactive Arthritis Update: Spotlight on New and Rare Infectious Agents Implicated as Pathogens. Curr Rheumatol Rep 2021;23(7):53.
  6. António Santos C, Trigueiros F, Machado Leite I. Reactive Arthritis. Eur J Case Rep Intern Med 2025;12(5):005350.
  7. Bentaleb I, Abdelghani KB, Rostom S, Amine B, Laatar A, Bahiri R. Reactive Arthritis: Update. Curr Clin Microbiol Rep 2020;7(4):124–32.
  8. Carter JD. Reactive arthritis: defined etiologies, emerging pathophysiology, and unresolved treatment. Infect Dis Clin North Am 2006;20(4):827–47.
  9. van de Beek D, Brouwer MC, Thwaites GE, Tunkel AR. Advances in treatment of bacterial meningitis. Lancet 2012;380:1693–702.
  10. Muthukumar N, Rajagopal V, Dhandapani S. Pneumococcal spinal infections: rare presentations and diagnostic pitfalls. J Neurosci Rural Pract 2015;6:395–8.
  11. Verma AS, Dwarika D. Reactive arthritis developing after pneumococcal conjunctivitis: a case report. J Med Case Rep 2007;1:2.
  12. Norrito RL, Mastrilli S, Fiorello F, Taormina G, Di Giorgi L, Ruggirello GMA, et al. When fever strikes twice: a case report of Streptococcus pneumoniae myelitis with delayed-onset reactive arthritis. Infect Dis Rep 2025;17(6):147.
  13. Pathak H, Marshall T. Post-streptococcal reactive arthritis: where are we now? BMJ Case Rep 2016;2016:bcr2016215676.
  14. Colmegna I, Cuchacovich R, Espinoza LR. HLA-B27-associated reactive arthritis: pathogenetic and clinical considerations. Clin Microbiol Rev 2004;17:348–69.
  15. Aviles RJ, Ramakrishna G, Mohr DN, et al. Poststreptococcal reactive arthritis in adults: a case series. Mayo Clin Proc 2000;75:144.
  16. Logan D, McKee PJ. Poststreptococcal reactive arthritis. J Am Podiatr Med Assoc 2006;96(4):362–6.
  17. Deighton C. Beta haemolytic streptococci and reactive arthritis in adults. Ann Rheum Dis 1993;52:475.
  18. Chun C, Kingsbury DJ. Poststreptococcal reactive arthritis: diagnostic challenges. Perm J 2019;23:18.304.
  19. Dheda K, Barry CE 3rd, Maartens G. Tuberculosis. Lancet 2016;387:1211–26.
  20. Higashiguchi M, Matsumoto T, Kitamura T, Nakajima T, Nishioka K, Kimura H, et al. Poncet’s Disease (Reactive Arthritis Associated with Tuberculosis). Intern Med 2022;61(21):3245–9.
  21. Stumpf MAM, Kffuri Filho JM, Lichtenstein A. Poncet’s disease: a reactive arthritis secondary to pulmonary tuberculosis. Clin Rheumatol 2022;41(5):1615–6.
  22. Rueda JC, Crepy MF, Mantilla RD. Clinical features of Poncet’s disease. From the description of 198 cases found in the literature. Clin Rheumatol 2013;32:929–35.
  23. Abdulaziz S, Almoallim H, Ibrahim A, et al. Poncet’s disease (reactive arthritis associated with tuberculosis): retrospective case series and review of literature. Clin Rheumatol 2012;31:1521–8.
  24. Singh YP, Roy D, Jois B, Shetti M. Reactive arthritis following treatment with intravesical Bacillus Calmette-Guerin for papillary carcinoma of bladder. BMJ Case Rep 2022;15(4):e249208.
  25. Endo Y, Kawashiri SY, Koga T, et al. Reactive arthritis induced by active extra-articular tuberculosis: a case report. Medicine (Baltimore) 2019;98:e18008.
  26. Pilianidis G, Tsinari A, Pandis D, Tsolakidou H, Petridis N. Chronic seronegative spondyloarthropathy following acute Mycoplasma pneumoniae infection in a human leukocyte antigen B27-positive patient: a case report. J Med Case Rep 2020;14(1):155.
  27. Bajantri B, Venkatram S, Diaz-Fuentes G. Mycoplasma pneumoniae: A Potentially Severe Infection. J Clin Med Res 2018;10(7):535–44.
  28. Blasco Patiño F, Pérez Maestu R, López de Letona JM. Mecanismos de enfermedad en la infección por Mycoplasma pneumoniae. Manifestaciones clínicas y complicaciones [Mechanisms of disease in Mycoplasma pneumoniae infection. Clinical manifestations and complications]. Rev Clin Esp 2004;204(7):365–8.
  29. Poddighe D, Abdukhakimova D, Dossybayeva K, Mukusheva Z, Assylbekova M, Rakhimzhanova M, et al. Mycoplasma pneumoniae Seroprevalence and Total IgE Levels in Patients with Juvenile Idiopathic Arthritis. J Immunol Res 2021;2021:6596596.
  30. Horino T, Inotani S, Matsumoto T, Ichii O, Terada Y. Reactive arthritis caused by Rothia mucilaginosa in an elderly diabetic patient. J Clin Rheumatol 2019;26:e303–4.
  31. Ma Y, Sun J, Che G, Cheng H. Systematic Infection of Chlamydia Pneumoniae. Clin Lab 2022;68(8):10.7754/Clin.Lab.2021.210908.
  32. Qureshi AM, Tariq S, Javed N, Sheikh AB. One Joint Aspirate: Three Diagnoses. Cureus 2021;13(9):e17714.
  33. Goedvolk CA, Von Rosenstiel IA, Bos AP. Immune complex associated complications in the subacute phase of meningococcal disease: incidence and literature review. Arch Dis Child 2003;88:927–30.
  34. Schaad UB. Arthritis in disease due to Neisseria meningitidis. Rev Infect Dis 1980;2:880–8.
  35. Dillon M, Nourse C, Dowling F, Deasy P, Butler B. Primary meningococcal arthritis. Pediatr Infect Dis J 1997;16:331–2.
  36. Bhavnagri S, Steele N, Massasso D, Benn R, Youssef P, Bleasel J. Meningococcal-associated arthritis: infection versus immune-mediated. Intern Med J 2008;38(1):71–3.
  37. Wen S, Feng D, Chen D, Yang L, Xu Z. Molecular epidemiology and evolution of Haemophilus influenzae. Infect Genet Evol 2020;80:104205.
  38. Desarden R, Caloia R. Polyarticular Septic Arthritis Caused by Haemophilus Influenzae in an Asplenic Patient: A Case Report. Clin Pract Cases Emerg Med 2025;9(1):78–81.
  39. Chohan A, Qureshi M, Huda M, et al. An unusual case of Haemophilus influenzae associated polyarthritis: diagnostic and therapeutic challenges in concurrent septic and reactive arthritis. Cureus 2024;16(11):e73194.
  40. Sanders B, Abdulfatah M, Aljuaid M, Tawhari I. Polyarticular septic arthritis due to non-typeable Haemophilus influenzae with concomitant new-onset acute gouty arthritis. J Investig Med High Impact Case Rep 2019;7:2324709619864990.
  41. Kareem Ali M, Shia JS. Erythema nodosum manifestation of Parvovirus B19-associated reactive arthritis. J Infect Dev Ctries 2024;18(9):1435–41.
  42. Mahmood AS, Al-Kazaz AKA, Ad’hiah AH. Single nucleotide polymorphism of IL1B Gene (rs16944) in a sample of rheumatoid arthritis Iraqi patients. Iraqi J Sci 2018;59:1041–5.
  43. Corcoran A, Doyle S. Advances in the biology, diagnosis and host–pathogen interactions of parvovirus B19. J Med Microbiol 2004;53:459–75.
  44. Kerr JR. Pathogenesis of human parvovirus B19 in rheumatic disease. Ann Rheum Dis 2000;59:672–83.
  45. Moore TL. Parvovirus-associated arthritis. Curr Opin Rheumatol 2000;12:289–94.
  46. Ogawa E, Otaguro S, Murata M, Kainuma M, Sawayama Y, Furusyo N, Hayashi J. Intravenous immunoglobulin therapy for severe arthritis associated with human parvovirus B19 infection. J Infect Chemother 2008;14:377–82.
  47. Ono K, Kishimoto M, Shimasaki T, Uchida H, Kurai D, Deshpande GA, et al. Reactive arthritis after COVID-19 infection. RMD Open 2020;6:e001350.
  48. Danssaert Z, Raum G, Hemtasilpa S. Reactive arthritis in a 37-year-old female with SARS-CoV2 infection. Cureus 2020;12(8):e9698.
  49. Liew IY, Mak TM, Cui L, Vasoo S, Lim XR. A case of reactive arthritis secondary to coronavirus disease 2019 infection. J Clin Rheumatol 2020;26(6):233.
  50. Coath FL, Mackay J, Gaffney JK. Axial presentation of reactive arthritis secondary to COVID-19 infection. Rheumatology (Oxford) 2021;60(7):e232-e233.
  51. Kobayashi S, Taniguchi Y, Kida I, Tamura N. SARS-CoV2-triggered acute arthritis: Viral arthritis rather than reactive arthritis. J Med Virol 2021;93(12):6458–9.
  52. Novelli L, Motta F, Ceribelli A, et al. A case of psoriatic arthritis triggered by SARS-CoV-2 infection. Rheumatology (Oxford) 2021;60:e21–3.
  53. Weisberg SP, Connors TJ, Zhu Y, et al. Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. Nat Immunol 2021;22:25–31.
  54. Golstein MA, Fagnart O, Steinfeld SD. Reactive arthritis after COVID-19 vaccination: 17 cases. Rheumatology (Oxford) 2023;62(11):3706–9.  2.